As some of you reading this know, it is my personal aim to continue to learn through mine and others traumatising lived experiences, to combining that with my ‘day job’ working with healthcare professionals and organisations to help raise awareness of issues that I and others have experienced that would benefit from more attention.
I’m delighted to be sharing the news that today, the 30th May 2022, a paper has been published, written be P-CNS. It can be read on one of the largest online medical education platforms in the UK, Onmedica.  Titled, ” What is like to hear life-altering medical news? Perspectives from health professionals” it provides a unique window into what it’s like for health professionals, who have had to hear the news themselves! It also shares how it can be stressful for this health professionals having to impart the news.
We hope it will be an article that will be shared with colleagues,  and it gives or supports a voice of many people who feel they haven’t been heard.
If you are non medical professional, (as Onmedica is intended for medical professionals), you can read the article on our website here
Best wishes


Neil Bindemann PhD
Executive Director

To reach any of our previous newsletters click here.

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Corporate Partner News

In this section our corporate partners can relay their latest news. Over the coming weeks we start to populate this page with news links.

For instance to read about the latest news from the Parkinson’s Excellence Network, click on the link below.

Click here!

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat.

Neurodigest News

Neurodigest is our journal produced in partnership with Advances in Clinical Neuroscience and Rehabilitation, designed to help keep you up to date with developments in neurology to support the management of people with neurological conditions in primary care and the wider community setting. Our latest newsletter can be read from here.

Advances in Clinical Neuroscience and Rehabilitation – Latest News

Advances in Clinical Neuroscience and Rehabilitation (ACNR) is a peer reviewed open access neurology journal, based in the UK and with international readership. ACNR aims to keep busy practicing neurologists and rehabilitation specialists up-to-date with the latest advances in their fields,  including areas of neurology and neuroscience outside their main area of sub-specialty interest. The latest ACNR newsletter can be read from here.


IBTA e-News

The monthly bulletin for our
international brain tumour community
November 2021

Leading news

Fifth Edition of the WHO Classification of CNS Tumours

The fifth edition of the World Health Organization (WHO) Classification of Central Nervous System (CNS) tumours is now available online. It was built on the 2016 updated fourth edition and the work of the classification consortium to inform molecular and practical approaches to classifying CNS tumours. Several major changes have been introduced in this fifth edition that take into account increased knowledge and advances in molecular diagnostics. The WHO Classification continues to emphasize the core relevance of integrated diagnoses and layered reports. Several new tumour types have been introduced in the WHO fifth edition based on novel diagnostic technologies such as DNA methylome profiling. A review of the updated Classification was also published online in August, 2021 which summarized the major general changes and the specific changes in each of the categories of CNS tumours. Read more.

SNO meeting in Boston

The Society for Neuro-Oncology (SNO) Annual Meeting took place in Boston, USA from 18-21 November. The meeting included the Education Day, Fellows’ Retreat, Plenary Sessions and Keynotes with updates in diagnosis and treatments of various central nervous system tumours, and abstract and poster sessions.  The Education Day included a session on Biomarkers and Precision Design for Clinical Trials and another session on Multidisciplinary Practice in Neuro-Oncology which featured education on disease management, treatment related toxicity, and coordination of care for the patient and caregiver.  Early, top-line results of the IBTA’s COVID-19 vaccines and brain tumour patients international survey were also presented at SNO. A full analysis of this IBTAsurvey is currently being prepared for publication.
Recordings from SNO sessions should be available mid-December for those who registered (registration is now closed and there is no further opportunity to register).  The SNO abstracts have been published in the Neuro-Oncologysupplement and can be found on the SNO website or directly through this link: https://academic.oup.com/neuro-oncology/issue/23/Supplement_6

IBTA Podcast Series – “A Brain Tumour and Me”

 The IBTA is proud to announce the launch of Episode 2 of its new podcast series, “A Brain Tumour and Me – a journey of inspiration, personal stories and hope”.  In this series, we’re meeting some of those working in the field of neuro-oncology, the people who support patients and their families and those who’ve been told they have a brain tumour. We’ll learn how brain tumours affected all these people, often in surprising ways.
The second episode of “A Brain Tumour and Me” features American neurosurgeon, author and researcher Dr Alfredo Quiñones-Hinojosa who talks about his remarkable journey from the humblest of beginnings in Mexicali, Mexico to becoming a renowned neurosurgeon and neuroscientist. Dr Quiñones-Hinojosa is the William J and Charles H Mayo Professor and Chair of Neurologic Surgery and runs a basic science research lab at the Mayo Clinic in Jacksonville, Florida, United States.  Dr Quiñones-Hinojosa’s research work focuses on brain tumours and cell migration, healthcare disparities and clinical outcomes for neurosurgical patients. In this latest IBTA podcast, Dr Quiñones-Hinojosa reveals the dramatic, life-changing accident he had at age 21 and how his brain tumour patients have inspired his work.
“A Brain Tumour and Me” is available via Apple Podcasts, Spotify, CastBox, Breaker, Anchor and the IBTA website at www.theibta.org/podcast. “A Brain Tumour and Me” has been produced by Graham Seaman Media for the IBTA.

Treatment news 

Intracranial germ cell tumours in adolescents and young adults: European and North American consensus review, current management and future development

 A comprehensive review has been published in the journal Neuro-Oncologydescribing the current management and future developments of intracranial germ cell tumours (iGCT). A European and North American cooperative group has formulated treatment strategies for this type of brain tumour.  The treatment recommendations are based on the extent of disease and include a combination of surgery and/or chemotherapy and radiation therapy. Read more.

Research news 

Final efficacy and safety analyses from the phase 3 CheckMate 548 trial of nivolumab

According to final efficacy and safety analyses of the phase 3 CheckMate 548 study (NCT02667587) that were presented at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting plenary session in Boston, United States, adding nivolumab to the standard of care radiation and temozolomide does not improve survival among patients with newly diagnosed glioblastoma.
Researchers investigated the safety and efficacy of adding nivolumab – a ‘checkpoint inhibitor’ drug that binds to a protein called PD-1 – to radiotherapy and chemotherapy in patients with newly diagnosed glioblastoma that had methylated or indeterminate MGMT promoter status. A total of 716 patients were randomized in equal groups to receive either nivolumab or placebo alongside standard care.The primary endpoints were progression-free survival (PFS) and overall survival (OS).

The median progression free survival was 10.6 months in the nivolumab group and 10.3 months in the placebo group. The median overall survival (OS) was 28.9 months in the nivolumab group and 32.1 months in the placebo group. In patients with a >5% PD-L1 expression, the median progression free survival was 8.4 months in the nivolumab group and 9.9 months in the placebo group. Grade 3 to 4 adverse events were noted in 52.4% of treated patients in the nivolumab group compared with 33.6% in the placebo group. Read more (free registration may be required).

Tumor Treating Fields (TTFields) in combination with pembrolizumab and adjuvant temozolomide improves progression free survival in glioblastoma, according to study

In a phase 2 pilot study called “2-THE-TOP” of 25 patients with newly-diagnosed glioblastoma, researchers found an increase in progression free survival when Tumor Treating Fields (TTFields) were combined with pembrolizumab and adjuvant temozolomide. In those patients with greater than nine months of follow-up, median progression-free survival (which was the primary endpoint), was at least 11.2 months with 24% of the patients having a complete or a partial response. Twelve patients were progression free and 15 were still alive at the time of release of data. The comparison arm was historical data from the EF-14 study in which patients received TTFields and adjuvant temozolomide. The results of the study were presented at the annual Society for Neuro-Oncology (SNO) conference in Boston, USA, this month.  Read more,

Combination treatment with dabrafenib and trametinib

In a study published in The Lancet Oncology, investigators found that a combination of two targeted cancer drugs showed “clinically meaningful” activity in patients with glioblastoma that carried a rare genetic mutation. The phase 2 efficacy trial called ROAR (Rare Oncology Agnostic Research) has been open to enrollment since 2014 in 13 countries. The study is a so-called “basket” trial where patients who share a common tumour characteristic (in this case the BRAF v600E mutation) but have different cancers, are enrolled in the same trial.

The researchers combined the two drugs dabrafenib and trametinib, both of which target proteins in the MAPK pathway, a signaling chain of proteins that works by regulating cell growth. The goal of the study is to determine the overall response rate of dabrafenib combined with trametinib in patients with BRAF V600E-mutated cancers. This combination has also been used to treat melanoma, non-small cell lung cancer, and thyroid cancer. The drug combination shrank tumours by >50% in one-third of 45 patients and three patients had complete responses. This study also includes patients with thyroid and biliary tract cancers, gastrointestinal stromal tumours, hairy cell leukemia, multiple myeloma, low- and high-grade glioma brain tumours, amongst others.  Read more: here and here.

Major UK study will look at whether cannabis extract-based drug Sativex can extend survival in glioblastoma

A three-year phase 2 trial (“ARISTOCRAT”) will be carried out by researchers at Leeds University in the UK led by professor of clinical oncology and neuro-oncology Dr Susan Short, to determine whether adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival.
Sativex is an oral spray containing cannabinoids THC and CBD (which is already licensed and sold by other companies in some markets for neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis). Glioblastoma cells have been shown to have receptors to cannabinoids on their cell surface, and lab studies suggest cannabinoid drugs may slow tumour growth.

The Leeds investigators aim to recruit more than 230 patients with glioblastoma at 15 NHS hospitals in the UK from March 2022, who will be treated after evidence of first disease progression following first-line radiotherapy and temozolomide chemotherapy .

The ARISTOCRAT study follows on from the positive results in an earlier trial where Sativex was given in combination with temozolomide in 27 patients. Researchers found that the regimen was well tolerated and showed evidence of improved progression-free survival (PFS) as well as overall survival (OS). Read more.

Researchers at NIH find increased financial toxicity and distress in brain tumour patients during the Covid-19 pandemic

In a study presented at the Annual Meeting of the Society for Neuro-Oncology (SNO) 2021 in Boston, USA, researchers from the Neuro-Oncology Branch (NOB) of National Institutes of Health (NIH) found that during the COVID-19 pandemic, patients with primary brain tumours faced greater ‘financial toxicity’ and distress. It is well known that brain tumour patients have a high symptom burden and functional limitations. The NIH researchers assessed financial toxicity and patient reported outcomes (PROs) from 112 participants in the NOB’s Natural History Study during the period from July 2020 to May 2021. Significantly, the researchers found that up to 56% of patients reported financial hardships due to their brain tumour diagnosis and half of patients reported feeling moderately to extremely anxious or depressed. Racial disparity was prominent among non-whites and Hispanics who reported greater financial burden compared with whites. Furthermore, participants who were unemployed had a worse financial burden than those who were employed. Lastly, worse financial toxicity scores strongly correlated with worse overall symptom burden, in particular anxiety and depression. The authors noted that future studies are needed to assess financial toxicity across time and especially post-pandemic. Read more (abstract).

Rare CNS tumours as a paradigm to expedite progress in CNS cancers and diseases

A review article published in Neuro-Oncology details the essential aspects of basic, translational, and clinical research in rare central nervous system (CNS) tumours. The article covers preclinical models, advances in tumour classification and molecular analysis and options for clinical trial design. It also includes incorporation of patient outcome measures in clinical care and clinical trials, and current models of multidisciplinary care in rare tumours of the CNS. Read more (full article).

Children’s Brain Tumor Network and genetic research on childhood tumours

The Children’s Brain Tumor Network (CBTN), a multi-institutional brain tumour research programme with funding from the Childhood Cancer Data Initiative of the National Cancer Institute (NCI), USA, is collecting tumour samples from patients at 26 member institutions all over the world. CBTN will procure molecular characterization for thousands of these brain tumour samples to provide an insight into brain cancers so that future therapeutic interventions can be developed.
This programme will support molecular characterization of greater than 3,000 germline samples and more than 1,500 tumour samples across all paediatric brain tumour types that have been collected by CBTN since 2011. Because childhood brain tumours are rare, collaborations like CBTN are crucial in advancing development of treatments. The more data that is available to researchers, the higher is the potential for novel insights leading to breakthroughs in treatment. Read more.

Study on nivolumab plus ipilimumab in patients with asymptomatic melanoma brain metastases: CheckMate 204 results announced

The final results of the landmark CheckMate 204 trial were published in TheLancet Oncology on November 10th. In patients with melanoma that has metastasized to the brain, combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab showed an improved overall survival. About 40% of patients with stage IV melanoma have brain metastases at diagnosis, whereas around 75% of melanoma patients will develop brain metastases at some point during the disease course. Historically, patients with brain metastases have been excluded from clinical trials and hence treatment options for this patient population were not studied. Combination checkpoint inhibitors have changed the landscape of treatment for melanoma with brain metastasis: prior to its introduction, the one-year survival rate for these patients was dismal at about 20%.

According to the study results, the overall survival rate from melanoma brain metastases is around 72% in asymptomatic patients at three years and in those who responded to treatment within 12 weeks, the overall survival was 92%. The overall survival was lower at around 36% in patients with symptomatic brain metastasis but remained durable. The intracranial progression-free survival was noted to be 54.1% at three years in asymptomatic patients and 18.9% in symptomatic patients. The checkpoint combination toxicity was similar to previous trials in advanced melanoma patients without brain metastases. Common treatment-related adverse events noted by the researchers were colitis, diarrhea, pituitary inflammation and elevated liver enzymes. Immune-mediated adverse events were hepatitis, rash and hypothyroidism. Read more (subscription/payment needed for full paper).

Experimental imaging approach using FET-PET in patients with glioblastoma

Researchers in Australia have announced a new trial, FIG, investigating an experimental imaging approach using FET-PET imaging technology in patients with glioblastoma. MRI plays a central role in diagnosis, radiation planning, and treatments in glioblastoma but can have certain limitations, especially with determining tumour progression. The aim of the FIG study is to accomplish a more accurate assessment of a glioblastoma and its response to treatments with the aim to improve outcomes. The primary goal of the trial is to find whether the imaging modality can provide any additional information to distinguish between treatment related changes (sometimes called ‘pseudoprogression’) and true tumour growth after initial treatment. TROG Cancer Research in Australia will be coordinating the multi-site prospective trial which will enroll up to 210 patients at ten sites.
The technique works by imaging a novel radiotracer (FET) that can detect the metabolic activity of cancer cells. The participants will receive standard of care radiotherapy and temozolomide chemotherapy. The participants will get the FET-PET scans at the time of starting treatments and after completing chemoradiation. In addition, study participants will be followed-up with a quality-of-life questionnaire in their clinical assessment at regular, pre-specified intervals and at the time when the routine FET-PET imaging is performed.  Read more (pdf).

Potential role of oral drug arginine to enhance radiation therapy for brain metastases

A paper has been published in Science Advances looking at the use of arginine to enhance the effect of radiation treatment in patients with brain metastases. Arginine, also called L-arginine, is an amino acid that is inexpensive and widely available. Arginine is used by the body to produce nitric oxide (NO). The researchers hypothesised that overloading a high-nitric acid (NO) tumour with more NO before radiation treatment could impair the tumour’s ability to repair radiation-induced DNA damage.

The researchers further report that arginine is generally considered safe and has a noticeable blood-brain barrier permeability. The researchers administered arginine to the 31 study participants who had brain metastases prior to standard radiation therapy. They found that only 22 percent of the 32 patients who received a placebo prior to radiotherapy had a complete or a partial response in their brain tumours over the follow-up period of up to four years whereas those patients who received arginine had a 78 percent response over a similar timeframe. The trial was designed as a proof-of-concept that arginine can be used as a radiosensitizer that enhances the effects of radiation treatment. The researchers also highlight that the results of the trial suggest that arginine could be useful more broadly in anticancer therapy. Read more here and here.

Barrow Neurological Institute to evaluate niraparib, a PARP inhibitor, in a Phase 0 clinical trial for patients with glioblastoma

In a collaboration between The Ivy Brain Tumor Center at Barrow Neurological Institute and the University of California San Francisco (UCSF), United States, niraparib, a PARP inhibitor, will be tested in a Phase 0 clinical trial in partnership with pharmaceutical company GSK. PARP inhibitors are a type of cancer drug. PARP stands for ‘poly adenosine diphosphate-ribose polymerase’, a type of enzyme that helps repair DNA damage in cells. These drugs are a form of targeted therapy. Niraparib is an orally administered, once-daily medication that is FDA-approved for advanced ovarian, fallopian tube, or primary peritoneal cancer. Niraparib has been shown to have a good bioavailability (the ability of a drug or other substance to be absorbed and used by the body) and a strong synergy with temozolomide in preclinical studies.

Enrolment will be open for patients with either a newly diagnosed glioblastoma or recurrent glioma (grades II – IV). The goal of the study, which is expected to recruit 42 participants, is to evaluate the medication’s pharmacokinetics (a drug’s absorption, distribution, metabolism and excretion from the body) and pharmacodynamics (the body’s response to a drug). Read more.

Antiseizure medication levetiracetam use during glioblastoma treatment may be correlated with a higher overall survival rate, study reports

A retrospective study published in Neurology reported that patients with glioblastoma who used antiseizure medication levetiracetam during treatments with chemotherapy or radiation therapy may have a higher overall survival rate. Seizures are common in brain tumours, ranging from 30% to 60% of patients. These are more common in patients with isocitrate dehydrogenase (IDH) mutant brain tumours than in IDH wild-type brain tumours. The researchers reviewed charts of 460 patients with IDH wild-type from 2010 to 2018. They found that among the patients who were on levetiracetam for the entirety of chemoradiation, median overall survival was 21 months whereas in patients who were on this medication part-time and those not on it, the overall survival was 16.8 months and 16 months, respectively. In conclusion, the researchers claim that only using levetiracetam for the entire duration or part of the chemoradiation was an independent factor in prolonging overall survival and the daily dose did not influence the outcome.
Furthermore, they found that O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and amount of tumour resection (partial or gross total resection) were also independent factors determining overall survival. The authors, however, noted that their study had limitations including the study design, clinical diagnosis of epileptic seizures, missing data for methylation status of MGMT promoter and absence of specifics on levetiracetam use. They also commented that further prospective multicentric controlled trials to investigate survival benefit of antiseizure medications would be required. Read more.

Combining repurposed disulfiram and copper shows activity in medulloblastoma

Researchers at Johns Hopkins University School of Medicine, USA, and Italy’s Catholic University of the Sacred Heart School of Medicine have published a study in PLOS One which describes combining copper ions with disulfiram (DSF) in the treatment of medulloblastoma. The treatment for pediatric medulloblastoma has been surgery, radiation, and chemotherapy used individually or in combination. Disulfiram has traditionally been used to treat chronic alcoholism and has shown promise repurposed as an anti-cancer agent particularly when combined with copper ions [Cu++].
Researchers tested the anti-cancer activity of DSF-Cu++ in cell cultures and in mice. The researchers found that DSF-Cu++ is lethal to medulloblastoma cells and also to its precursor stem cells in these cell cultures and mice. They also found that DSF-Cu++ impairs the DNA-repair machinery of medulloblastoma cells. Damage to DNA, if not repaired, promotes apoptosis which is a biological mechanism to remove dysfunctional cells. It also blocks the two common biological pathways that medulloblastoma cancer cells use to remove toxic proteins making them more prone to lethal damage. When tested in mice implanted with medulloblastoma tumours, the combination also showed a significant improvement in survival, according to the researchers. Read more.

Study reports new drug combinations identified with activity in highly aggressive childhood DIPG brain tumours

In a pre-clinical study published in Cancer Discovery, researchers have identified a combination of MEK inhibitor drug trametinib and multi-kinase inhibitor drug, dasatinib that slowed the growth of cancer cells obtained from patients with diffuse intrinsic pontine glioma (DIPG). These two drugs are already approved for treating other cancers. DIPG is a rare pediatric brain cancer which is universally fatal with a majority of patients dying within a year of diagnosis. DIPG tumour cells often develop resistance to targeted therapies. Trametinib alone had little effect in mice experiments however when dasatinib was used in combination with it, there was a slowing of tumour growth in cells resistant to trametinib. The combination will be tested in further animal studies and if it shows promising results, will be tested in clinical trials. Trametinib is approved for use in adults for melanoma skin cancer and non-small cell lung cancer. Dasatinib is used in chronic myeloid leukemia. Read more.

Yale School of Public Health researchers awarded US $13 Million to study low grade gliomas

Low grade gliomas (LGGs) are brain tumours that are a challenge to manage because of slow and gradual growth. Researchers at Yale School of Public Health in the United States have been awarded US $13 million to study the biology of these tumours in a large-scale research project. The scientists plan to enroll 500 patients with LGGs and will perform a comprehensive genomic characterization of the tumours and investigate their evolution. The research effort, named “OPTimIzing engageMent in discovery of molecular evolUtion of low grade glioMa, (OPTIMUM)” is funded by the National Cancer Institute (NCI).

The goal of this multi-institutional study is also to learn more about the effect of this diagnosis and its associated treatments on daily life including the ability to work, drive, sleep, exercise, or take care of oneself and/or a family member. The current study will build upon the existing International Low Grade Glioma Registry but focus on people with recurrent low grade glioma to understand how treatment may change the genetic makeup of these tumours. Read more.

Company news

Chimerix announces positive topline results for ONC201 in recurrent H3 K27M-mutant glioma

Biopharmaceutical company Chimerix has reported positive data from its efficacy analysis of Onc201 for the treatment of recurrent H3 K27M-mutant glioma. Onc201 is an orally administered small molecule that works as an antagonist at the dopamine receptor D2 (DRD2) and an agonist at caseinolytic protease (ClpP) receptor in recurrent gliomas that harbour the H3 K27M mutation.

The study was conducted in 50 patients in both paediatric and adult populations enrolled across five ONC201 clinical studies who met the eligibility criteria. The eligibility criteria included measurable diffuse midline glioma with an H3 K27M mutation and evidence of disease progression following treatment with radiation completed at least 90 days prior to trial enrolment. The study results were presented at the Society for Neuro-Oncology (SNO) Annual Meeting on November 20, 2021.

Onc 201 has been granted FDA approval for H3 K27M-mutant high-grade glioma Fast Track Designation under Rare Pediatric Disease Designation and Orphan Drug Designation. Read more (company press release).

Daiichi Sankyo launches its oncolytic virus therapy Delytact in Japan as a treatment for malignant glioma

A genetically engineered oncolytic herpes simplex virus type 1 (HSV-1), Delytact was approved for marketing in Japan earlier this year. The approval was based on data from a single-arm phase 2 trial in patients with residual or recurrent glioblastoma previously treated with radiotherapy and temozolomide chemotherapy in which Delytact showed an improved overall survival at one year.

The virus is constructed to be directly lethal to the tumor cells without affecting normal tissues. It is injected directly into the tumor up to six times. It is commercially available only at sites which had participated in the clinical trial. Read more here and here.

Kazia Therapeutics announces enrolment of first patient in PNOC childhood brain cancer study

Kazia Therapeutics Limited has announced that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient successfully enrolled to the study. PNOC022 includes Kazia’s investigational drug, paxalisib among the experimental arms and is expected to provide valuable data on the potential use of the drug in this highly aggressive childhood brain cancer. The study will examine multiple therapies concurrently, both as single agents and in combination, to determine the optimal approach to treatment. The study employs an adaptive design, in which different arms will be opened and closed based on emerging preclinical and clinical data. Read more.

Conference, workshop and meeting news

Due to the current COVID-19 pandemic, many in-person meetings and conferences around the world have been cancelled, postponed, or converted to virtual events. We are trying our best to keep up with this news but please make sure you check with conference organisers as to the status of their scheduled events.


Society for Neuro-Oncology Sub-Saharan Africa (SNOSSA) First Thursday education series: Paediatric radiotherapy
2 December 2021

Flash Radiotherapy and Particle Therapy Conference
1-3 December 2021

4th Annual Miami Brain Symposium (Virtual)
3 December 2021

39th Annual Meeting of the Japan Society for Neuro-Oncology
5-7 December 2021
Kobe, Japan

SNO Maximal Safe Brain Tumor Resection: Intraoperative Visualization and the Connectome Conference
6-7 December 2021

6th ESO-ESMO-RCE Clinical Update on Rare Solid Cancers
16 December 2021
Pre-recorded sessions
29-30 January 2022

6th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS) and 17th Meeting of the Asian Society for Neuro-Oncology (ASNO)
24-27 March 2022
Seoul, South Korea

SNOG-FiBTRA Symposium 2022
Joint Symposium of the Scandinavian Society of Neuro-Oncology and the Finnish Brain Tumor Research Association
19-21 May 2022
Tampere, Finland

SIOP Europe Brain Tumor Group Meeting
11-12 June 2022
Hamburg, Germany

20th International Symposium on Paediatric Neuro-Oncology (ISPNO 2022)
12-15 June 2022
Hamburg, Germany

15th International Stereotactic Radiosurgery Society Congress
19-23 June 2022
Milan, Italy

British Neuro-Oncology Society Annual Meeting 2022 (BNOS2022)
22-24 June 2022
Liverpool, UK

Brain Tumors Meeting 2022 – From Biology to Therapy
22-24 June 2022
Warsaw, Poland

Posterior Fossa Society – First Global Meeting
9-11 September 2022
Liverpool, UK

16th Congress of the European Association of Neuro-Oncology (EANO)
15-18 September 2022
Vienna, Austria

27th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO 2022)
16-20 November 2022
Tampa, Florida, USA

If you are organising or are aware of a forthcoming patient or brain tumour advocacy event or a scientific conference, whether it is virtual or in-person, taking place in 2021 or 2022 or are aware of any changes to the listings above, then please let us know by emailing kathy@theibta.org so that we can also include new events on our events page.

Keep up to date with future scientific conferences and events on the IBTAwebsite conferences page here.


The International Brain Tumour Alliance (IBTA) makes every effort to be accurate regarding the information contained in this e-News (or in any documents, reports, notes or other material produced for and on behalf of the IBTA to which we provide a link in this e-News).  However, the IBTA accepts no liability for any inaccuracies or omissions herein nor can it accept liability for any loss or damage resulting from any inaccuracy in this information or third party information such as information on websites to which we link. The information contained in this e-News is for educational purposes only and should in no way be taken as a substitute for medical care nor is the information on the IBTA website meant to constitute medical advice or professional services. For medical care and advice, please contact your doctor. Inclusion of clinical trial news does not imply the IBTA’s particular endorsement or not of any trial.

Other websites linked from the IBTA e-News are not under the control of the IBTA. Therefore we take no responsibility for their content. The IBTA has provided these links as a convenience to you and can in no way verify the information, quality, safety or suitability of linked websites.

Any company sponsorship of the IBTA’s projects does not imply the IBTA’s endorsement of any particular form or forms of therapy, treatment regimen or behaviour. (For further details of our sponsors, please see our Sponsorship Policy).

The views and opinions in the materials included in this e-News may not necessarily be those of the International Brain Tumour Alliance.

The Sleep Charity: July Bulletin

Click here to read the Sleep Charity’s latest bulletin.